Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Klinic vs Tell Her Doc

Klinic
Graded #313

Higher grade

vs+3.5999999999999943
Tell Her Doc
Graded #404

Lower grade

The verdict

Klinic takes it — 60.8/100 to 57.2/100.

Klinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Klinic is a LegitScript-certified multi-condition telehealth platform prescribing brand-name GLP-1 medications—Wegovy (semaglutide) and Zepbound (tirzepatide)—to patients across all 50 U.S.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKlinic +18
45
27
Dose & formulationTell Her Doc +10
53
63
Clinical oversightKlinic +3
79
76
Labs & monitoringKlinic +12
64
52
FulfillmentTell Her Doc +7
76
83
Contract termsTell Her Doc +6
55
61
Klinic · left barTell Her Doc · right bar

The numbers

MetricKlinicTell Her Doc
WeighScore60.8/10057.2/100
GradeCC
Scorecard rank#313#404
SemaglutideNot disclosed$269/mo (microdose tier, plus a separate fee, compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Klinic

Graded #313 · C

Strengths

  • LegitScript certified, licensed in all 50 states, DEA registered, HIPAA/SOC 2 Type II compliant
  • Broad insurance acceptance including Medicare, Medicaid, BCBS, Aetna, Cigna, UHC, and Humana
  • Klinic handles all prior authorization—patient never manages PA paperwork
  • Brand-name FDA-approved GLP-1s (Wegovy, Zepbound) at full clinical doses with home delivery
  • Named clinical leadership (CMO Dr. Saba Haq, Chief Physician Dr. Vivek Chander) and disclosed founder

Where it loses points

  • Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
  • No compounded semaglutide or tirzepatide option for patients seeking lower-cost alternatives
  • Medication cost is separate from visit fees ($99 initial, $75 follow-up) — total self-pay cost is higher
  • No labs or dedicated nutrition/coaching program included in any plan
  • Pharmacy fulfillment via Klinic Pharmacy Hub Services LLC (non-dispensing hub); actual dispensing is third-party
Tell Her Doc

Graded #404 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

Where it loses points

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard